HC Wainwright Reaffirms “Buy” Rating for Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $80.00 price objective on the stock.

SLN has been the subject of several other reports. Robert W. Baird upped their target price on shares of Silence Therapeutics from $50.00 to $53.00 in a research note on Thursday, January 26th. Morgan Stanley initiated coverage on shares of Silence Therapeutics in a research note on Friday, December 9th. They set an “equal weight” rating and a $18.00 target price for the company. Finally, Chardan Capital cut their target price on shares of Silence Therapeutics from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $8.70 on Friday. The stock has a market cap of $260.39 million, a P/E ratio of -5.58 and a beta of 0.88. Silence Therapeutics has a one year low of $7.80 and a one year high of $21.32. The company has a fifty day moving average price of $12.34 and a 200 day moving average price of $12.61.

Hedge Funds Weigh In On Silence Therapeutics

Want More Great Investing Ideas?

A number of hedge funds have recently made changes to their positions in SLN. Millennium Management LLC grew its holdings in shares of Silence Therapeutics by 19.8% in the 4th quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock worth $266,000 after purchasing an additional 2,879 shares during the last quarter. UBS Group AG grew its holdings in shares of Silence Therapeutics by 4.8% in the 4th quarter. UBS Group AG now owns 69,006 shares of the company’s stock worth $1,052,000 after purchasing an additional 3,191 shares during the last quarter. Citadel Advisors LLC grew its holdings in shares of Silence Therapeutics by 99.7% in the 3rd quarter. Citadel Advisors LLC now owns 22,851 shares of the company’s stock worth $226,000 after purchasing an additional 11,410 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Silence Therapeutics in the 4th quarter worth about $450,000. Finally, UBS Oconnor LLC grew its holdings in shares of Silence Therapeutics by 176.4% in the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company’s stock worth $786,000 after purchasing an additional 50,820 shares during the last quarter.

Silence Therapeutics Company Profile

(Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.